Engineered Probiotic with a Molecular Switch: Glucose-Sensing Bacteria Produce GLP-1 Only When Blood Sugar Is High

Forum topic · 小凯 · 2026-08-15

Summary

Researchers at East China Normal University (Ye Haifeng and Guan Ningzi teams) have developed GIFT, a synthetic biology platform published in Nature (August 12, 2026), that turns the probiotic Escherichia coli Nissle 1917 into a self-regulating diabetes therapy. The engineered bacteria carry a 'sense-and-respond' gene circuit: when blood glucose rises, glucose metabolism produces the metabolite KDPG, which binds the HexR transcriptional regulator from Pseudomonas putida, lifting repression and switching on GLP-1 expression. As glucose falls, KDPG declines, the repression closes, and drug production stops—creating a closed-loop feedback resembling pancreatic islet function. In db/db diabetic mice, 30 days of oral GIFT improved fasting glucose, glucose tolerance, insulin sensitivity, and HbA1c, while reducing hepatic steatosis, kidney injury, and gut inflammation. In spontaneously diabetic cynomolgus monkeys, a single oral dose lowered blood sugar for up to three days. With over 530 million people living with diabetes worldwide, GIFT could replace open-loop fixed-dosing regimens with an adaptive living medicine, though human safety, colonization persistence, dosing precision, and regulatory hurdles remain before clinical translation.

Insulin injections and GLP-1 drugs are daily routines for hundreds of millions of people with diabetes. The problem: this dosing is 'open-loop'—drugs enter the body at a fixed rhythm regardless of current blood sugar. Low glucose raises hypoglycemia risk; high glucose may go under-controlled. Could drugs work like islets, producing medicine only when they sense high glucose and stopping when it drops?

On August 12, 2026, a team led by Ye Haifeng and Guan Ningzi at East China Normal University published a platform called GIFT in *Nature* that does exactly this. The approach follows the standard synthetic biology playbook: decompose complex biological systems into standardized modules, then reassemble them with gene circuits. The team chose *Escherichia coli* Nissle 1917 (EcN), a probiotic with a century-long safety record, as the engineering chassis, and implanted it with a 'sense–compute–actuate' gene circuit.

How the Molecular Switch Works

The sensing module is a 'molecular lock': the HexR transcriptional regulator protein from *Pseudomonas putida*. When blood glucose rises, the bacteria metabolize glucose to produce a small metabolite called KDPG. KDPG acts as a 'molecular key' that fits into the lock, releasing repression and initiating expression of the therapeutic gene GLP-1. When glucose falls back, KDPG decreases, the lock closes, and drug production stops. This is the so-called Sense-and-Respond mode—essentially rebuilding a closed-loop feedback similar to human pancreatic islets.

Validation Across Two Species

Mice: In db/db diabetic mouse models, 30 consecutive days of oral GIFT produced serum GLP-1 levels that rose and fell precisely with blood glucose fluctuations. Fasting blood glucose, glucose tolerance, insulin sensitivity, and HbA1c all improved significantly, with simultaneous relief of hepatic steatosis, kidney injury, and intestinal inflammation.
Non-human primates: In a spontaneous type 2 diabetes cynomolgus monkey model, a single oral dose of GIFT delivered a glucose-lowering effect lasting up to 3 days.

From mice to monkeys, this closed loop proved stable.

Why It Matters

Global diabetes cases have exceeded 530 million. Even with GLP-1 drugs like semaglutide improving outcomes, the hypoglycemia risk and adverse effects of 'open-loop' continuous dosing remain pressing pain points. If an oral probiotic can produce medicine in closed-loop response to blood glucose, it effectively replaces 'daily injections' with 'a colony of microbes that do the work themselves.'

Remaining Challenges

1. Human safety: The colonization persistence and long-term safety of oral bacteria have not yet been validated in humans. 2. Generalization: GLP-1 is only one pathway in diabetes. Whether this Sense-and-Respond framework can extend to other hormones and metabolic diseases requires more gene circuits. 3. Clinical translation: Delivery dosing and individualized control precision for engineered bacteria still face regulatory and manufacturing hurdles.

Paradigm Shift

What GIFT changes is the paradigm: moving 'dosing' from external timed delivery to an in vivo adaptive biological feedback device. The endpoint of this path is not necessarily diabetes—any chronic disease requiring 'real-time response to physiological state' could theoretically adopt the same framework. A 3-day effect in the monkey model is already enough to move 'living medicine' one step from concept toward the clinic.